|
GB201815447D0
|
|
Pharmaceutical Compounds
|
|
GB201704966D0
|
|
Pharmaceutical compounds
|
|
GB201704965D0
|
|
Pharmaceutical compounds
|
|
US2017224705A1
|
|
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201700867D0
|
|
Pharmaceutical compounds
|
|
KR20180095580A
|
|
Quinoline-3-carboxamide as H-PGDS inhibitor
|
|
TW201726647A
|
|
Pharmaceutical compounds
|
|
CA2999400A1
|
|
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
|
|
AU2016279388A1
|
|
NRF2 regulators
|
|
TW201642903A
|
|
Fgfr/pd-1 combination therapy for the treatment of cancer
|
|
US2016287699A1
|
|
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
HK1211922A1
|
|
Pyrazolyl quinazoline kinase inhibitors
|
|
CN106456648A
|
|
Combinations of FGFR inhibitor and IGIR inhibitor
|
|
WO2015144804A1
|
|
Combinations
|
|
JO3512B1
|
|
Quinoxaline derivatives useful as fgfr kinase modulators
|
|
JOP20200201A1
|
|
Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
|
|
NZ719905A
|
|
Bicyclic heterocycle compounds and their uses in therapy
|
|
WO2015004481A1
|
|
Imidazo-condensed bicycles as inhibitors of discoidin domain receptors (ddrs)
|
|
GB201406986D0
|
|
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201322755D0
|
|
Bicyclic heterocycle compounds and their uses in therapy
|
